AgomAb Therapeutics

Belgian immunology and inflammatory biotech AgomAb Therapeutics files for a $100 million US IPO February 6, 2026 News Belgian fibrotic disease biotech AgomAb Therapeutics prices IPO at $16 midpoint, raising $200 million AgomAb Therapeutics, a Belgian Phase 2 biotech developing... Read more